- |||||||||| Clinical, Review, Journal: Two challenging cases of pituicytoma. (Pubmed Central) - Feb 25, 2022
Pituicytomas are known to be low-grade tumors; because of their rarity, they are a real challenge. These patients should be followed up closely.
- |||||||||| hydroxychloroquine / Generic mfg., dexamethasone / Generic mfg.
Observational data, Journal: COVID-19 treatments sold online without prescription requirements in the United States. (Pubmed Central) - Feb 25, 2022
We document that illegitimate online pharmacies sidestep prescription requirements, skirt pharmacist counselling, and make false claims regarding efficacy in treating COVID-19 infections. Health care professionals must urgently educate the public of the dangers of purchasing drugs from illegitimate websites and highlight the importance of seeking treatment through authentic avenues of care.
- |||||||||| Darzalex IV (daratumumab) / J&J
Clinical, P3 data, Journal: Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. (Pubmed Central) - Feb 25, 2022
P3
Our study reveals the importance of systemic immunity in regulating PAH-induced skin pigmentation, and provide a new keratinocyte DNA damage response mechanistic target for the prevention or reversal of pollution-associated skin pigmentation. A clear, maintained progression-free survival benefit of KdD over Kd with longer follow-up was confirmed, making KdD an emerging standard-of-care for patients with relapsed or refractory multiple myeloma.
- |||||||||| Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
Journal, HEOR: Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial. (Pubmed Central) - Feb 25, 2022
Results were similar in a subgroup of patients recommended triple therapy in the 2019 National Institute for Health and Care Excellence COPD guideline. FF/UMEC/VI single-inhaler triple therapy improved health outcomes and was a cost-effective option compared with FF/VI or UMEC/VI for patients with symptomatic COPD and a history of exacerbations in the UK at recognised cost-effectiveness threshold levels.
- |||||||||| diazepam / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Journal: Oral anxiolytics prior to routine resident cataract surgery eliminate need for intravenous sedation at a Veterans Affairs Hospital. (Pubmed Central) - Feb 25, 2022
Pre-operative placement of an intravenous (IV) catheter, administration of intra-operative IV sedation, oral diazepam administration, anesthesia type, conditions for administering intraoperative IV medication, and cost of IV catheter placement were recorded...One patient received a planned dose of IV methylprednisolone...Pre-operative IV catheter placement may not be necessary in patients undergoing routine resident cataract surgery with pre-operative oral sedation. Discontinuation of routine IV placement may improve patient satisfaction and decrease health care costs without compromising patient safety.
- |||||||||| dexamethasone / Generic mfg.
Journal: Antenatal dexamethasone for late preterm birth: A multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial. (Pubmed Central) - Feb 25, 2022
This trial was primarily funded by the Bill and Melinda Gates Foundation (Grant OPP1136821). Additional support was provided by UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Sexual and Reproductive Health and Research; and Department of Maternal, Newborn, Child, Adolescent Health, and Ageing, of the World Health Organization, Geneva, Switzerland.
- |||||||||| H.P. Acthar Gel (repository corticotropin injection) / Mallinckrodt
Trial termination: A Trial of Neuroprotection With ACTH in Acute Optic Neuritis (clinicaltrials.gov) - Feb 25, 2022
P4, N=100, Terminated,
Additional support was provided by UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Sexual and Reproductive Health and Research; and Department of Maternal, Newborn, Child, Adolescent Health, and Ageing, of the World Health Organization, Geneva, Switzerland. Active, not recruiting --> Terminated; Sponsor requested
- |||||||||| mometasone furoate / Generic mfg.
Observational data, Journal: Topical Steroid Damaged Face: A Cross-Sectional Study from Saudi Arabia. (Pubmed Central) - Feb 25, 2022
The most used TCs were Mometasone furoate 0.1% cream (18.2%), followed by Fusidic acid/Betamethasone cream (16.7%)...A large population are not aware of the side effects of the unsupervised use of TCs. An effort should be made to increase awareness of the adverse effects of TCs.
- |||||||||| dexamethasone / Generic mfg.
Journal: Interdependent Transcription of a Natural Sense/Antisense Transcripts Pair (SLC34A1/PFN3). (Pubmed Central) - Feb 25, 2022
Five-day exposure to dexamethasone significantly stimulates sense transcript (SLC34A1) levels and antisense (PFN3) minimally; the effect is only seen in HEK293 cells...Accordingly, we propose that in somatic cells, NATs act like lncRNAs-with the benefit of close proximity to a potential target gene. In germ cells, however, recent evidence suggests different biological roles for NATs that require RNA complementarity and double-stranded RNA formation.
- |||||||||| Decadron (dexamethasone) / Merck (MSD), Hemady (dexamethasone tablets) / Dexcel Pharma
Trial completion date, Trial primary completion date, Combination therapy, Metastases: NCI-2018-01103: Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer (clinicaltrials.gov) - Feb 25, 2022
P2/3, N=70, Recruiting,
In germ cells, however, recent evidence suggests different biological roles for NATs that require RNA complementarity and double-stranded RNA formation. Trial completion date: May 2022 --> May 2023 | Trial primary completion date: May 2022 --> May 2023
- |||||||||| Trial completion date, Trial initiation date, Trial primary completion date: Effect of Corticosteroid Injections on Blood Glucose (clinicaltrials.gov) - Feb 25, 2022
P2, N=124, Not yet recruiting,
N=117 --> 66 Trial completion date: May 2025 --> Jun 2024 | Initiation date: Jan 2022 --> Apr 2022 | Trial primary completion date: Jan 2024 --> Apr 2024
- |||||||||| relacorilant (CORT125134) / Corcept Therap
New P3 trial, Combination therapy, Monotherapy, Metastases: ROSELLA: Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (clinicaltrials.gov) - Feb 25, 2022
P3, N=360, Not yet recruiting,
- |||||||||| hydrocortisone / Generic mfg.
Journal: What Is the Role of Steroids for Septic Shock in 2021? (Pubmed Central) - Feb 24, 2022
In this review, we explore the current evidence supporting the use of corticosteroids in septic shock, its benefits, and potential harms. In addition to landmark clinical trials, we will also describe new frontiers for the use of corticosteroids in septic shock which should be explored in future studies.
- |||||||||| fluticasone / Generic mfg.
Preclinical, Journal: Sarsasapogenin and fluticasone combination improves DNFB induced atopic dermatitis lesions in BALB/c mice. (Pubmed Central) - Feb 24, 2022
These data specify that SG has been demonstrated as a probable therapy for the treatment of allergic skin diseases in combination with FC by decreasing its dose from 50 to 25 µg/mice to avoid the chronic side effects of FC. Hence, it can be concluded that SG and SG + FC combination significantly improved the AD-like symptoms in the DNFB sensitized mice through mitigating the production of proinflammatory mediators and restoration of oxidative stress markers.
- |||||||||| dexamethasone / Generic mfg.
Preclinical, Journal: A Systematic Approach for Liposome and Lipodisk Preclinical Formulation Development by Microfluidic Technology. (Pubmed Central) - Feb 24, 2022
The EE of negative Log P compounds, like acyclovir, remained low regardless of altering the D/L ratio and PEG concentrations...Both liposome and lipodisk of curcumin demonstrated enhanced in vivo performance compared with a conventional formulation in the rat pharmacokinetic study. This combination of approaches with multiple model compounds and lipid-based drug delivery systems provides a systematic guidance to effective strategies to generate higher EE with minimal drug waste and expedite the process for preclinical development when applied to industry compounds.
- |||||||||| methylprednisolone sodium succinate / Generic mfg.
Journal: Post-COVID-19 longitudinally extensive transverse myelitis: is it a new entity? (Pubmed Central) - Feb 24, 2022
Whether post-infectious myelitis behaves differently from other viral infections after COVID-19 is currently unclear. Long lag times appear to be a post-infectious neurological complication resulting from the host response to the virus.
- |||||||||| budesonide / Generic mfg.
Journal: Preparation and Characterization of Colon-Targeted pH/Time-Dependent Nanoparticles Using Anionic and Cationic Polymethacrylate Polymers. (Pubmed Central) - Feb 24, 2022
To overcome the inadequacy of only pH-dependent delivery systems, we developed in vitro evaluated both pH- and time-dependent nanoparticles loaded budesonide (BUD) for the treatment of IBD in this study...Nanoparticles containing 90% anionic-10% cationic polymethacrylate polymers inhibited burst BUD release under acidic conditions and exhibited sustained drug release at neutral pH. Consequently, in the medication of IBD, BUD-loaded pH and time-dependent nanoparticles may be a hopeful choice as a drug delivery system.
- |||||||||| dexamethasone / Generic mfg.
Journal: Potential Application of Alternative Materials for Organic Pollutant Removal. (Pubmed Central) - Feb 24, 2022
The work aims to synthesize and characterize vegetal charcoal (or biochar) from Syzygium cumini (AC-SC), evaluating the adsorption capacity for dexamethasone drug (DEX) removal, using the kinetic and equilibrium adsorption...About the equilibrium and kinetic adsorption, the Sips model and pseudo-second order showed the best experimental data adjusted, indicating that the adsorption monolayer was dependent on the ions onto the biosorbent, with a maximum adsorption capacity of 0.744 mg g after 180 min. Therefore, AC-SC can be used as an alternative material in the removal of organic pollutants, such as drug removal.
- |||||||||| dexamethasone / Generic mfg.
Journal: Comparison between methylprednisolone infusion and dexamethasone in COVID-19 ARDS mechanically ventilated patients. (Pubmed Central) - Feb 24, 2022
Four hundred fourteen patients had COVID-19 pneumonia, diagnosed and confirmed by ground glass opacities in chest tomography and arterial partial pressure of oxygen/inspired oxygen and fraction of inspired oxygen (P/F ratio) less than 300.Two hundred twenty-two patients received methylprednisolone infusion at a dose of 2 mg/kg/day, and 192 patients received dexamethasone 6 mg daily; both groups were treated for 10 days.Inflammatory markers for cytokine storm were improved in the methylprednisolone group in comparison to the patients who were given dexamethasone when comparing the on-admission markers to the results of the inflammatory markers after 10 days, like ferritin after 10 days in methylprednisolone group 292.26 ± 330.10 versus the dexa group 648.10 ± 329.09 (p value < 0.001).D-dimer in the methylprednisolone group was 1301.75 ± 1515.51 versus 2523.78 ± 843.18 in the dexa group (p value < 0.001); CRP was 49.65 ± 19.91 in the methylprednisolone group versus 100.54 ± 36.75 (p value < 0.001) in the dexa group; LDH after 10 days in methylprednisolone group was 345.09 ± 128.31, and in the dexa group, it was 731.87 ± 195.09 (p value < 0.001); neutrophil to lymphocyte ratio (N:L ratio) after 10 days of treatment in the methylprednisolone group was 17.27 ± 5.09 versus 26.68 ± 7.19 (p value < 0.001) in the dexa group; also, the length of stay was shorter in the methylprednisolone group (7.33 ± 1.71) versus in the dexa group (19.43 ± 5.42) (p value < 0.001), together with mechanical ventilation MV days which are 3.82 ± 1.14 in the methyl group versus 16.57 ± 4.71 in the dexa group (p value < 0.001).Also, the radiological findings are improved in the methyl group (20.3%) versus the dexa group (73.4%) with p value < 0.001, and discharge from ICU in the methyl group was 79.7% versus 26.6% in the dexa group with p value < 0.001. Treatment of severe COVID-19 pneumonia, Patients who were mechanically ventilated with methylprednisolone infusion 2 mg/kg/day for 10 days versus dexamethasone 6 mg for 10 days showed a statistically significant improvement in the MV days and length of stay in the intensive care unit, together with the overall mortality and severity inflammatory markers of cytokine storm c-reactive protein (CRP), D-dimer, ferritin, LDH, and N:L ratio.
- |||||||||| dordaviprone (ONC201) / Chimerix
Trial completion date, Trial primary completion date: Oral ONC201 in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 24, 2022
P1/2, N=21, Active, not recruiting,
Treatment of severe COVID-19 pneumonia, Patients who were mechanically ventilated with methylprednisolone infusion 2 mg/kg/day for 10 days versus dexamethasone 6 mg for 10 days showed a statistically significant improvement in the MV days and length of stay in the intensive care unit, together with the overall mortality and severity inflammatory markers of cytokine storm c-reactive protein (CRP), D-dimer, ferritin, LDH, and N:L ratio. Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Jun 2021 --> Jun 2022
- |||||||||| iberdomide (CC-220) / BMS
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy: CC-220-MM-001: A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma (clinicaltrials.gov) - Feb 24, 2022
P1b/2a, N=464, Recruiting,
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Jun 2021 --> Jun 2022 Trial completion date: Oct 2027 --> Feb 2028 | Trial primary completion date: Aug 2021 --> Apr 2022
|
